1. Home
  2. ABLV vs SABS Comparison

ABLV vs SABS Comparison

Compare ABLV & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$0.83

Market Cap

41.1M

Sector

N/A

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.94

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
SABS
Founded
2015
2014
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.1M
181.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ABLV
SABS
Price
$0.83
$3.94
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.50
AVG Volume (30 Days)
1.1M
345.7K
Earning Date
01-02-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$114,319,869.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$17.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$1.00
52 Week High
$1.77
$6.60

Technical Indicators

Market Signals
Indicator
ABLV
SABS
Relative Strength Index (RSI) 49.87 59.18
Support Level $0.74 $3.54
Resistance Level $0.85 $4.03
Average True Range (ATR) 0.13 0.27
MACD 0.01 -0.01
Stochastic Oscillator 22.83 87.82

Price Performance

Historical Comparison
ABLV
SABS

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: